Phase I Evaluation of Crisnatol (BWA770U Mesylate) on a Monthly Extended Infusion Schedule

Patrick W. Cobb; Kathleen A. Havlin; John G. Kuhn; John B. Craig; Glenn S. Harman; J. Scott Luther; Judy N. Turner; Geoffrey R. Weiss; Dennis A. Tweedy; Jim Koeller; Richard L. Tuttle; V. Sol Lucas; William Wargin; John K. Whisnant; Daniel D. Von Hoff

doi:10.1089/sct.1991.7.85

Phase I Evaluation of Crisnatol (BWA770U Mesylate) on a Monthly Extended Infusion Schedule

Patrick W. Cobb, Kathleen A. Havlin, John G. Kuhn, John B. Craig, Glenn S. Harman, J. Scott Luther, Judy N. Turner, Geoffrey R. Weiss, Dennis A. Tweedy, Jim Koeller, Richard L. Tuttle, V. Sol Lucas, William Wargin, John K. Whisnant, Daniel D. Von Hoff

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

Crisnatol is an arylmethylaminopropanediol derivative that has shown promise as an antitumor agent in preclinical testing. In a phase I trial using a monthly six-hour infusion schedule the recommended dose for future phase II trials was found to be 388 mg/m². Neurologic toxicity was dose-limiting in that trial and correlated with the attainment of a threshold plasma concentration of >4.5 μg/ml. In this study we treated 15 patients with escalating doses of crisnatol from 450 mg/m² to 900 mg/m² administered at a rate of 50 mg/m²/hr over 9, 12, 15, and 18 hours. Toxicity was mild to moderate at all dose levels. However, serious central nervous system effects were noted in one patient at 900 mg/m² over 18 hours whose plasma level was 6.5 μg/ml. This study has demonstrated higher total doses of crisnatol can be given if the drug is administered as a prolonged infusion in an attempt to avoid high plasma levels of the agent.

Original language	English (US)
Pages (from-to)	85-91
Number of pages	7
Journal	Selective Cancer Therapeutics
Volume	7
Issue number	2
DOIs	https://doi.org/10.1089/sct.1991.7.85
State	Published - 1991

ASJC Scopus subject areas

Pharmacology
Cancer Research

Access to Document

10.1089/sct.1991.7.85

Cite this

Cobb, P. W., Havlin, K. A., Kuhn, J. G., Craig, J. B., Harman, G. S., Luther, J. S., Turner, J. N., Weiss, G. R., Tweedy, D. A., Koeller, J., Tuttle, R. L., Lucas, V. S., Wargin, W., Whisnant, J. K., & Von Hoff, D. D. (1991). Phase I Evaluation of Crisnatol (BWA770U Mesylate) on a Monthly Extended Infusion Schedule. Selective Cancer Therapeutics, 7(2), 85-91. https://doi.org/10.1089/sct.1991.7.85

Cobb, PW, Havlin, KA, Kuhn, JG, Craig, JB, Harman, GS, Luther, JS, Turner, JN, Weiss, GR, Tweedy, DA, Koeller, J, Tuttle, RL, Lucas, VS, Wargin, W, Whisnant, JK & Von Hoff, DD 1991, 'Phase I Evaluation of Crisnatol (BWA770U Mesylate) on a Monthly Extended Infusion Schedule', Selective Cancer Therapeutics, vol. 7, no. 2, pp. 85-91. https://doi.org/10.1089/sct.1991.7.85

@article{43182d4ec92e4138bd49e85d54e45f26,

title = "Phase I Evaluation of Crisnatol (BWA770U Mesylate) on a Monthly Extended Infusion Schedule",

abstract = "Crisnatol is an arylmethylaminopropanediol derivative that has shown promise as an antitumor agent in preclinical testing. In a phase I trial using a monthly six-hour infusion schedule the recommended dose for future phase II trials was found to be 388 mg/m2. Neurologic toxicity was dose-limiting in that trial and correlated with the attainment of a threshold plasma concentration of >4.5 μg/ml. In this study we treated 15 patients with escalating doses of crisnatol from 450 mg/m2 to 900 mg/m2 administered at a rate of 50 mg/m2/hr over 9, 12, 15, and 18 hours. Toxicity was mild to moderate at all dose levels. However, serious central nervous system effects were noted in one patient at 900 mg/m2 over 18 hours whose plasma level was 6.5 μg/ml. This study has demonstrated higher total doses of crisnatol can be given if the drug is administered as a prolonged infusion in an attempt to avoid high plasma levels of the agent.",

author = "Cobb, {Patrick W.} and Havlin, {Kathleen A.} and Kuhn, {John G.} and Craig, {John B.} and Harman, {Glenn S.} and Luther, {J. Scott} and Turner, {Judy N.} and Weiss, {Geoffrey R.} and Tweedy, {Dennis A.} and Jim Koeller and Tuttle, {Richard L.} and Lucas, {V. Sol} and William Wargin and Whisnant, {John K.} and {Von Hoff}, {Daniel D.}",

year = "1991",

doi = "10.1089/sct.1991.7.85",

language = "English (US)",

volume = "7",

pages = "85--91",

journal = "Selective Cancer Therapeutics",

issn = "1043-0733",

publisher = "Mary Ann Liebert Inc.",

number = "2",

}

TY - JOUR

T1 - Phase I Evaluation of Crisnatol (BWA770U Mesylate) on a Monthly Extended Infusion Schedule

AU - Cobb, Patrick W.

AU - Havlin, Kathleen A.

AU - Kuhn, John G.

AU - Craig, John B.

AU - Harman, Glenn S.

AU - Luther, J. Scott

AU - Turner, Judy N.

AU - Weiss, Geoffrey R.

AU - Tweedy, Dennis A.

AU - Koeller, Jim

AU - Tuttle, Richard L.

AU - Lucas, V. Sol

AU - Wargin, William

AU - Whisnant, John K.

AU - Von Hoff, Daniel D.

PY - 1991

Y1 - 1991

N2 - Crisnatol is an arylmethylaminopropanediol derivative that has shown promise as an antitumor agent in preclinical testing. In a phase I trial using a monthly six-hour infusion schedule the recommended dose for future phase II trials was found to be 388 mg/m2. Neurologic toxicity was dose-limiting in that trial and correlated with the attainment of a threshold plasma concentration of >4.5 μg/ml. In this study we treated 15 patients with escalating doses of crisnatol from 450 mg/m2 to 900 mg/m2 administered at a rate of 50 mg/m2/hr over 9, 12, 15, and 18 hours. Toxicity was mild to moderate at all dose levels. However, serious central nervous system effects were noted in one patient at 900 mg/m2 over 18 hours whose plasma level was 6.5 μg/ml. This study has demonstrated higher total doses of crisnatol can be given if the drug is administered as a prolonged infusion in an attempt to avoid high plasma levels of the agent.

AB - Crisnatol is an arylmethylaminopropanediol derivative that has shown promise as an antitumor agent in preclinical testing. In a phase I trial using a monthly six-hour infusion schedule the recommended dose for future phase II trials was found to be 388 mg/m2. Neurologic toxicity was dose-limiting in that trial and correlated with the attainment of a threshold plasma concentration of >4.5 μg/ml. In this study we treated 15 patients with escalating doses of crisnatol from 450 mg/m2 to 900 mg/m2 administered at a rate of 50 mg/m2/hr over 9, 12, 15, and 18 hours. Toxicity was mild to moderate at all dose levels. However, serious central nervous system effects were noted in one patient at 900 mg/m2 over 18 hours whose plasma level was 6.5 μg/ml. This study has demonstrated higher total doses of crisnatol can be given if the drug is administered as a prolonged infusion in an attempt to avoid high plasma levels of the agent.

UR - http://www.scopus.com/inward/record.url?scp=0025999604&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025999604&partnerID=8YFLogxK

U2 - 10.1089/sct.1991.7.85

DO - 10.1089/sct.1991.7.85

M3 - Article

C2 - 1754731

AN - SCOPUS:0025999604

VL - 7

SP - 85

EP - 91

JO - Selective Cancer Therapeutics

JF - Selective Cancer Therapeutics

SN - 1043-0733

IS - 2

ER -

Phase I Evaluation of Crisnatol (BWA770U Mesylate) on a Monthly Extended Infusion Schedule

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this